Levamlodipine/telmisartan - Chong Kun Dang

Drug Profile

Levamlodipine/telmisartan - Chong Kun Dang

Alternative Names: CKD-345; CKD-828; CKD-828(FDC); S-amlodipine/telmisartan; Telminuvo Tab; Telmisartan/S-amlodipine; Telmunivo

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chong Kun Dang
  • Class Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Nicotinic-acids; Small molecules
  • Mechanism of Action ACE inhibitors; Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypertension(Combination therapy, In volunteers) in South Korea (PO, Tablet)
  • 01 Jun 2015 Chong Kun Dang Pharmaceutical completes a phase I pharmacokinetics study in Healthy volunteers in South Korea (NCT02358824)
  • 01 Feb 2015 Chong Kun Dang Pharmaceutical initiates enrolment in a phase I pharmacokinetics study in Healthy volunteers in South Korea (NCT02358824)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top